


General experimental methods. Nuclear magnetic resonance spectra were measured operating at 400 MHz (^1H NMR) and at 100 MHz ($^{13}\text{C}\{^1\text{H}\}$ NMR). ^1H NMR chemical shifts were reported in ppm relative to the resonance in TMS at δ 0.00. $^{13}\text{C}\{^1\text{H}\}$ NMR chemical shifts were reported in ppm relative to the residual solvent signals of CDCl_3 at δ 77.16. High resolution mass spectra (HRMS) were recorded with APCI-TOF. Melting points were measured with Mettler Toledo MP90. UV-vis spectra were acquired with JASCO V-750 spectrometer. PL spectra measurement was conducted with JASCO FP-8500 Spectro Fluoro Photometer. PLQY measurement was conducted with HAMAMATSU C11347 absolute PL quantum yield spectrometer with an integrating sphere. Fluorescence lifetime measurement was conducted on a HAMAMATSU C11366 fluorescence lifetime spectrometer. Ground samples for the fluorescence measurement were prepared by placing a spatulaful of bisbenzofuropyrazines on a 2 cm square quartz plate and manually grinding with a mortar for about 1 minute.

These compounds were previously reported in the literature: 2-bromo-4-(*sec*-butyl)phenol,^{S1)} 2,5-bis(2-bromo-4-methylphenoxy)pyrazine,^{S2)} 2,8-dimethylbis(benzofuro)[2,3-*b*:2',3'-*e*]pyrazine.^{S2)}



Scheme S1. Synthetic routes toward **Linear-R**. i) *N*-bromosuccinimide, *p*-TsOH·H₂O, 2 h; ii) K₂CO₃, DMSO, 160 °C; iii) PdCl₂(PPh₃)₂, PivOK, DMAc, 160 °C, 15 h.


General synthetic method of bromophenol

To a stirred solution of 4-alkylphenol (1.0 eq.) and *p*-TsOH·H₂O (10 mol %) in MeOH (0.5 M) was added NBS (1.0 eq.) in one portion. The reaction mixture was stirred at RT for 2 h and then concentrated in vacuo. To the resulting mixture, hexane was added, and filtered. The filtrate was dried over Na₂SO₄/silica gel, and then concentrated in vacuo. The obtained product was directly used in the next step without further purification.

General synthetic method of 2,6-bis(2-bromo-4-alkylphenoxy)pyrazine


A mixture of 2-bromo-4-alkylphenol (2.0 eq.), 2,5-dibromopyrazine (1.0 eq.), and K₂CO₃ (2.4 eq.) in DMSO (1.0 M) was heated at 160 °C for 24 h. After the reaction was quenched with water, the mixture extracted with EtOAc. The organic layer was washed with water, dried over Na₂SO₄, and evaporated. The residue was purified by silica gel column chromatography (hexane/EtOAc = 40/1) to give the product.

2,5-bis(2-bromo-4-ethylphenoxy)pyrazine




822 mg (86%, 2.0 mmol scale); white solid; m.p. 129.5–131.1 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.96 (s, 2H), 7.48 (d, *J* = 2.09 Hz, 2H), 7.18 (dd, *J* = 2.07, 8.26 Hz, 2H), 7.10 (d, *J* = 8.45 Hz, 2H), 2.66 (q, *J* = 7.61 Hz, 4H), 1.26 (t, *J* = 7.78 Hz, 6H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 155.9, 148.6, 143.1, 132.9, 130.4, 128.2, 123.0, 115.9, 28.0, 15.2; HRMS (APCI) *m/z* (M+H⁺) calcd for C₂₀H₁₉Br₂N₂O₂: 476.9808, found: 476.9817.

2,5-bis(2-bromo-4-propylphenoxy)pyrazine




951 mg (94%, 2.0 mmol scale); white solid; m.p. 81.3-82.6 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.95 (s, 2H), 7.46 (d, J = 1.97 Hz, 2H), 7.15 (dd, J = 2.03, 8.20 Hz, 2H), 7.09 (d, J = 8.20 Hz, 2H), 2.58 (t, J = 7.88 Hz, 4H), 1.69-1.60 (m, 4H), 0.96 (t, J = 7.45 Hz, 6H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3) δ 155.91, 148.69, 141.70, 133.50, 130.41, 128.78, 122.93, 115.81, 37.14, 24.34, 13.80; HRMS (APCI) m/z (M+H $^+$) calcd for $\text{C}_{22}\text{H}_{23}\text{Br}_2\text{N}_2\text{O}_2$: 505.0121, found: 505.0133.

2,5-bis(2-bromo-4-isopropylphenoxy)pyrazine




2577 mg (92%, 5.5 mmol scale); brown solid; m.p. 86.1-87.8 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.95 (s, 2H), 7.48 (d, J = 2.11 Hz, 2H), 7.19 (ddd, J = 0.37, 8.30 Hz, 2H), 7.09 (d, J = 8.30 Hz, 2H), 2.95-2.85 (m, 2H), 1.26 (s, 6H), 1.24 (s, 6H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3) δ 155.9, 148.7, 147.7, 131.6, 130.4, 126.8, 123.0, 115.8, 33.5, 23.9; HRMS (APCI) m/z (M+H $^+$) calcd for $\text{C}_{22}\text{H}_{23}\text{Br}_2\text{N}_2\text{O}_2$: 505.0121, found: 505.0132.

2,5-bis(2-bromo-4-butylphenoxy)pyrazine




849 mg (79%, 2.0 mmol scale); white solid; m.p. 71.9-73.2 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.95 (s, 2H), 7.46 (d, J = 2.00 Hz, 2H), 7.16 (dd, J = 2.00, 8.24 Hz, 2H), 7.08 (d, J = 8.24, 2H), 2.60 (t, J = 7.80 Hz, 4H), 1.64-1.55 (m, 4H), 1.41-1.32 (m, 4H), 0.94 (t, J = 7.38 Hz, 6H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3) δ 155.9, 148.6, 141.9, 133.4, 130.4, 128.7, 122.9, 115.8, 34.4, 33.3, 22.3, 13.9; HRMS (APCI) m/z (M+H $^+$) calcd for $\text{C}_{24}\text{H}_{27}\text{Br}_2\text{N}_2\text{O}_2$: 533.0434, found: 533.0444.

2,5-bis(2-bromo-4-(sec-butyl)phenoxy)pyrazine




2754 mg (94%, 5.5 mmol scale); orange oil; ^1H NMR (400 MHz, CDCl_3) δ 7.86 (s, 2H), 7.36 (d, J = 2.11 Hz, 2H), 7.07 (dd, J = 2.11, 8.24 Hz, 2H), 7.01 (d, J = 2.11, 8.24 Hz, 2H), 2.56-2.47 (m, 2H), 1.50 (d, J = 7.28 Hz, 4H), 1.15 (d, J = 6.98 Hz, 6H), 0.76 (t, J = 7.28 Hz, 6H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3) δ 155.9, 148.7, 146.6, 132.1, 130.4, 127.4, 122.8, 115.7, 40.9, 31.1, 21.6, 12.1; HRMS (APCI) m/z (M+H $^+$) calcd for $\text{C}_{24}\text{H}_{27}\text{Br}_2\text{N}_2\text{O}_2$: 533.0434, found: 533.0450.

2,5-bis(2-bromo-4-pentylphenoxy)pyrazine




589 mg (70%, 1.5 mmol scale); white solid; m.p. 50.2-52.6 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.88 (s, 2H), 7.37 (d, *J* = 1.85 Hz, 2H), 7.08 (dd, *J* = 1.85, 8.44 Hz, 2H), 7.00 (d, *J* = 8.24 Hz, 2H), 2.52 (t, *J* = 7.90 Hz, 4H), 1.58-1.49 (m, 4H), 1.27-1.25 (m, 8H), 0.83 (t, *J* = 6.86 Hz, 6H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 155.9, 148.6, 141.9, 133.4, 130.4, 128.7, 122.9, 115.8, 35.0, 31.4, 30.9, 22.5, 14.0; HRMS (APCI) *m/z* (M+H⁺) calcd for C₂₆H₃₁Br₂N₂O₂: 561.0747, found: 561.0765.

2,5-bis(2-bromo-4-(*tert*-amyl) phenoxy)pyrazine



1641 mg (58%, 5.0 mmol scale); brown solid; m.p. 146.3-147.3 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.94 (s, 2H), 7.56 (d, *J* = 2.31 Hz, 2H), 7.29 (dd, *J* = 2.31, 8.55 Hz, 2H), 7.10 (d, *J* = 8.55 Hz, 2H), 1.63 (q, *J* = 7.56 Hz, 4H), 1.28 (s, 12H), 0.71 (t, *J* = 7.56 Hz, 6H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 155.8, 148.6, 148.4, 131.3, 130.3, 126.4, 122.4, 115.5, 37.8, 36.8, 28.3, 9.1; HRMS (APCI) *m/z* (M+H⁺) calcd for C₂₆H₃₁Br₂N₂O₂: 561.0747, found: 561.0765.

2,5-bis(2-bromo-4-hexylphenoxy)pyrazine



1130 mg (96%, 2.0 mmol scale); white solid; m.p. 62.2-63.6 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.96 (s, 2H), 7.46 (d, *J* = 1.91 Hz, 2H), 7.16 (dd, *J* = 2.05, 8.47 Hz, 2H), 7.08 (d, *J* = 8.22 Hz, 2H), 2.56 (t, *J* = 8.01 Hz, 4H), 1.65-1.57 (m, 4H), 1.38-1.26 (m, 12H), 0.89 (t, *J* = 6.94 Hz, 6H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 155.9, 148.6, 141.9, 133.4, 130.4, 128.7, 122.9, 115.8, 35.1, 31.6, 31.2, 28.9, 22.6, 14.1; HRMS (APCI) *m/z* (M+H⁺) calcd for C₂₈H₃₅Br₂N₂O₂: 589.1060, found: 589.1062.

2,5-bis(2-bromo-4-cyclohexylphenoxy)pyrazine



2355 mg (80%, 5.0 mmol scale); brown solid; m.p. 117.9-118.6 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.96 (s, 2H), 7.47 (d, *J* = 2.03 Hz, 2H), 7.18 (dd, *J* = 2.03, 8.29 Hz, 2H), 7.09 (d, *J* = 8.29 Hz, 2H), 2.52-2.47 (m, 2H), 1.90-1.84 (m, 8H), 1.77-1.73 (m, 2H), 1.44-1.32 (m, 8H), 1.28-1.21 (m, 2H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 155.8, 148.6, 146.9, 131.9, 130.4, 127.1, 122.8, 115.7, 43.7, 34.3, 26.7, 26.0; HRMS (APCI) *m/z* (M+H⁺) calcd for C₂₈H₃₁Br₂N₂O₂: 585.0747, found: 585.0757.

General synthetic method of Linear-R

A mixture of 2,5-bis(2-bromo-4-alkylphenoxy)pyrazine (1.0 eq.), PdCl₂(PPh₃)₂ (20 mol%), PivOK (4.0 eq.), DMAc (0.16 M) was heated at 160 °C for 15 h. After the reaction was completed, the reaction was quenched with water, and then extracted with EtOAc. The organic layer was washed with water, dried over Na₂SO₄, and evaporated. The residue was purified by silica gel column chromatography (hexane/EtOAc = 20/1) and GPC (CHCl₃) to give the product.

2,8-diethylbis(benzofuro)[2,3-*b*:2',3'-*e*]pyrazine (Linear-Et**)**

59 mg (47%, 0.4 mmol scale); white solid; m.p. 200.1-201.6 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.07 (dd, *J* = 0.67, 1.86 Hz, 2H), 7.62 (d, *J* = 8.52 Hz, 2H), 7.48 (dd, *J* = 1.90, 8.54 Hz, 2H), 2.86 (q, *J* = 7.62 Hz, 4H), 1.36 (t, *J* = 7.56 Hz, 6H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 155.6, 155.4, 140.4, 132.8, 130.4, 121.8, 120.2, 112.3, 28.8, 15.9; HRMS (APCI) *m/z* (M+H⁺) calcd for C₂₀H₁₇N₂O₂: 317.1285, found: 317.1287.

2,8-dipropylbis(benzofuro)[2,3-*b*:2',3'-*e*]pyrazine (Linear-nPr**)**

61 mg (45%, 0.4 mmol scale); white solid; m.p. 177.8-179.1 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.03 (d, *J* = 1.29 Hz, 2H), 7.60 (d, *J* = 8.53 Hz, 2H), 7.48 (dd, *J* = 1.84, 8.55 Hz, 2H), 2.78 (t, *J* = 7.58 Hz, 4H), 1.80-1.70 (m, 4H), 1.00 (t, *J* = 7.36 Hz, 6H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 155.5, 155.4, 138.8, 132.7, 130.9, 121.7, 120.9, 112.2, 37.8, 24.8, 13.7; HRMS (APCI) *m/z* (M+H⁺) calcd for C₂₂H₂₁N₂O₂: 345.1598, found: 345.1599.

2,8-diisopropylbis(benzofuro)[2,3-*b*:2',3'-*e*]pyrazine (Linear-iPr**)**

157 mg (46%, 1.0 mmol scale); white solid; m.p. 218.4-219.2°C; ¹H NMR (400 MHz, CDCl₃) δ 8.13 (d, *J* = 1.91 Hz, 2H), 7.64 (d, *J* = 8.37 Hz, 2H), 7.52 (dd, *J* = 1.91, 8.37 Hz, 2H), 3.16-3.08 (m, 2H), 1.38 (s, 6H), 1.37 (s, 6H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 155.6, 155.4, 145.2, 132.8, 129.3, 121.7, 118.8, 112.3, 34.1, 24.3; HRMS (APCI) *m/z* (M+H⁺) calcd for C₂₂H₂₁N₂O₂: 345.1598, found: 345.1602.

2,8-dibutylbis(benzofuro)[2,3-*b*:2',3'-*e*]pyrazine (Linear-nBu**)**

70 mg (47%, 0.4 mmol scale); white solid; m.p. 158.6-160.5 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.06 (d, *J* = 1.29 Hz, 2H), 7.62 (d, *J* = 8.48 Hz, 2H), 7.46 (dd, *J* = 1.85, 8.71 Hz, 2H), 2.82 (t, *J* = 7.86 Hz, 4H), 1.75-1.67 (m, 4H), 1.46-1.35 (m, 4H), 0.97 (t, *J* = 7.42 Hz, 6H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 155.6, 155.4, 139.1, 132.7, 130.9, 121.7, 120.8, 112.2, 35.4, 33.9, 22.2, 13.9; HRMS (APCI) *m/z* (M+H⁺) calcd for C₂₄H₂₅N₂O₂: 373.1911, found: 373.1913.

2,8-di(*sec*-butyl) bis(benzofuro)[2,3-*b*:2',3'-*e*]pyrazine (Linear-sBu**)**

13 mg (4%, 0.9 mmol scale); white solid; m.p. 168.2-169.0 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.07 (d, J = 1.77 Hz, 2H), 7.63 (d, J = 8.57 Hz, 2H), 7.47 (dd, J = 1.77, 8.57 Hz, 2H), 2.86-2.78 (m, 2H), 1.75-1.67 (m, 4H), 1.36 (d, J = 6.93 Hz, 6H), 0.87 (t, J = 7.28 Hz, 6H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 155.6, 155.4, 143.9, 132.8, 129.7, 121.7, 119.5, 112.3, 41.7, 31.4, 22.2, 12.2; HRMS (APCI) *m/z* (M+H⁺) calcd for C₂₄H₂₅N₂O₂: 373.1911, found: 373.1909.

2,8-dipentylbis(benzofuro)[2,3-*b*:2',3'-*e*]pyrazine (Linear-nAmyl**)**

57 mg (36%, 0.4 mmol scale); white solid; m.p. 152.1-153.5 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.04 (d, J = 1.32 Hz, 2H), 7.60 (d, J = 8.50 Hz, 2H), 7.44 (dd, J = 1.82, 8.43 Hz, 2H), 2.80 (t, J = 8.25 Hz, 4H), 1.76-1.69 (m, 4H), 1.40-1.30 (m, 8H), 0.92-0.89 (m, 6H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 155.5, 155.3, 139.1, 132.7, 130.9, 121.7, 120.8, 112.2, 35.7, 31.4, 31.3, 22.5, 14.0; HRMS (APCI) *m/z* (M+H⁺) calcd for C₂₆H₂₉N₂O₂: 401.2224, found: 401.2237.

2,8-di(*tert*-pentyl)bis(benzofuro)[2,3-*b*:2',3'-*e*]pyrazine (Linear-tAmyl**)**

111 mg (28%, 1.0 mmol scale); white solid; m.p. 213.9-214.4 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.22 (t, J = 1.32 Hz, 2H), 7.65 (d, J = 1.32 Hz, 4H), 1.77 (q, J = 7.50 Hz, 4H), 1.42 (s, 12H), 0.73 (t, J = 7.50 Hz, 6H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 155.6, 155.1, 145.8, 132.9, 128.6, 121.4, 118.8, 112.0, 38.3, 37.1, 28.9, 9.1 HRMS (APCI) *m/z* (M+H⁺) calcd for C₂₆H₂₉N₂O₂: 401.2224, found: 401.2243.


2,8-dihexylbis(benzofuro)[2,3-*b*:2',3'-*e*]pyrazine (Linear-nHex**)**


82 mg (48%, 0.4 mmol scale); white solid; m.p. 144.6-146.0 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.05 (d, J = 1.29 Hz, 2H), 7.61 (d, J = 8.51 Hz, 2H), 7.46 (dd, J = 1.86, 8.54 Hz, 2H), 2.81 (t, J = 7.55 Hz, 4H), 1.75-1.68 (m, 4H), 1.40-1.30 (m, 12H), 0.89 (t, J = 6.87 Hz, 6H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 155.6, 155.4, 139.1, 132.7, 130.9, 121.7, 120.8, 112.2, 35.8, 31.78, 31.72, 28.8, 22.6, 14.1; HRMS (APCI) *m/z* (M+H⁺) calcd for C₂₈H₃₃N₂O₂: 429.2537, found: 429.2541.


2,8-dicyclohexylbis(benzofuro)[2,3-*b*:2',3'-*e*]pyrazine (Linear-cHex**)**


17 mg (30%, 0.15 mmol scale); white solid; m.p. 271.1-272.2 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.09 (d, J = 1.89 Hz, 2H), 7.62 (d, J = 8.72 Hz, 2H), 7.49 (dd, J = 1.89, 8.72 Hz, 2H), 2.74-2.67 (m, 2H), 2.00-1.91 (m, 4H), 1.89-1.81 (m, 4H), 1.79-1.78 (m, 2H), 1.56-1.40 (m, 8H), 1.36-1.25 (m, 2H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 155.6, 155.4, 144.4, 132.8, 129.7, 121.7, 119.1, 112.2, 44.5, 34.9, 26.9, 26.1; HRMS (APCI) *m/z* (M+H)⁺ calcd for C₂₈H₂₉N₂O₂: 425.2224, found: 425.2213.


^1H and $^{13}\text{C}\{^1\text{H}\}$ NMR spectra of intermediate


























^1H and $^{13}\text{C}\{\text{H}\}$ NMR spectra of **Linear-Et**




^1H and $^{13}\text{C}\{\text{H}\}$ NMR spectra of **Linear-*n*Pr**




^1H and $^{13}\text{C}\{\text{H}\}$ NMR spectra of **Linear-iPr**




^1H and $^{13}\text{C}\{^1\text{H}\}$ NMR spectra of **Linear-*n*Bu**




^1H and $^{13}\text{C}\{^1\text{H}\}$ NMR spectra of **Linear-sBu**




^1H and $^{13}\text{C}\{^1\text{H}\}$ NMR spectra of **Linear-*n*Amyl**




^1H and $^{13}\text{C}\{^1\text{H}\}$ NMR spectra of **Linear-tAmyl**



^1H and $^{13}\text{C}\{^1\text{H}\}$ NMR spectra of **Linear-*n*Hex**



^1H and $^{13}\text{C}\{\text{H}\}$ NMR spectra of **Linear-cHex**






Figure S1. Changes of PXRD patterns of a) Form 1 crystal of **Linear-Et**, b) Form 2 crystal of **Linear-Et**, c) Form 1 crystal of **Linear-cHex**, and d) Form 2 crystal of **Linear-cHex** upon heating.




Figure S2. Differential scanning calorimetry measurements of **Linear-Et** Form 1, Form 2 and **Linear-cHex** Form 1, and Form 2.




Figure S3. Free volume fractions of **Linear-R** obtained by Multiwfn 3.8 (dev) package.^{S3)}




Figure S4. Fluorescence spectra and photographs of crystal and ground powder of a) **Linear-Et** Form 1, b) **Linear-Et** Form 2, c) **Linear-nPr**, d) **Linear-nBu**, e) **Linear-sBu**, f) **Linear-nAmyl**, and g) **Linear-nHex** under UV light irradiation.




Figure S5. Changes of the IR spectra of **Linear-iPr** before and after grinding.




Figure S6. Picture of the fast self-recovery behavior of **Linear-Et** Form 1 upon grinding.




Figure S7. PXRD pattern changes before and after grinding of a) **Linear-Me**, b) **Linear-iPr**, c) **Linear-tAmyl**, d) Form 1 of **Linear-cHex**, and e) Form 2 of **Linear-cHex**.




Figure S8. Intermolecular potentials among adjacent molecules in the crystalline state calculated at B3LYP-D3/6-311G** level. a) crystal of **Linear-tAmyl**, b) Form 1 crystal of **Linear-cHex**, c) Form 2 crystal of **Linear-cHex**.^{S4,S5}

The crystal of **Linear-cHex** Form 1 and 2, which showed smaller change in their spectral shapes upon grinding, had larger potential energy along the π stacking direction (-21.26, and -16.30 kcal/mol, respectively). In contrast, **Linear-tAmyl**, which exhibited distinct mechanochromic luminescence, had the smallest potential energy (-15.32 kcal/mol).




Figure S9. Fluorescence spectra of ground powder of **Linear-Me** after 0 h and 24 h.




Figure S10. PXRD patterns of pristine, ground powder, and ground powder after 1 d of a,b) **Linear-iPr**, c,d) **Linear-tAmyl**, e,f) Form 1 of **Linear-cHex**, and g,h) Form 2 of **Linear-cHex**.




Figure S11. Heating and CHCl₃ fuming effects on self-recovery process of a) **Linear-*iPr***, b) **Linear-*tAmyl***, c) Form 1 of **Linear-*cHex***, and d) Form 2 of **Linear-*cHex***.




Figure S12. PXRD pattern changes of the ground powder exposed to CHCl_3 vapor. a) **Linear-*iPr***, b) **Linear-*tAmyl***, c) **Linear-*cHex* Form 1**, and d) **Linear-*cHex* Form2**.




Figure S13. PXRD pattern changes of the ground powder heated at 100°C . a) **Linear-*iPr***, b) **Linear-*tAmyl***, c) **Linear-*cHex* Form 1**, and d) **Linear-*cHex* Form2**.




Figure S14. The corresponding peak wavelength treated by CHCl₃ fuming and grinding versus repeating cycle. a) **Linear-*iPr***, b) **Linear-*tAmyl***, c) Form 1 of **Linear-*cHex***, and d) Form 2 of **Linear-*cHex***.

Table S1. Luminescence quantum yields (QY) and free volume fraction (FVF).

Type-B			Type-D		
compd. (Linear-)	QY (-)	FVF (%)	compd. (Linear-)	QY (-)	FVF (%)
<i>iPr</i>	0.21	31.37	<i>nHex</i>	0.29	32.85
Me	0.28	30.14	<i>nPr</i>	0.35	31.88
Et Form 1	0.41	30.13	<i>nAmyl</i>	0.44	32.48
<i>cHex Form 1</i>	0.52	29.9	<i>nBu</i>	0.49	31.88
			Et Form 2	0.67	28.63

Table S2. Interaction energy between stacked two BBFPz molecules ^{S4,S5}.

Linear-	Et	<i>nPr</i>	<i>nBu</i>	<i>nAmyl</i>	<i>nHex</i>
E_{int} [kcal/mol] ^[a]	-16.72	-17.08	-19.12	-20.13	-21.53

a) Interaction energy was calculated at the B3LYP-D3/6-311G** level.

Table S3. Crystal Data of **Linear-Me**: CCDC-2305891

Empirical Fomura	C ₁₈ H ₁₂ N ₂ O ₂		
Formula weight	288.31		
Crystal System	monoclinic		
Space Group	<i>P</i> 2 ₁ /c (#14)		
Unit cell dimensions	<i>a</i> = 9.4411	α = 90	
	<i>b</i> = 6.1954	β = 91.836	
	<i>c</i> = 11.6634	γ = 90	
<i>V</i>	681.86 Å ³		
<i>Z</i>	4		
Density (calculated)	1404 g/cm ³		
R1 [I>2σ(I)]	0.0406		
wR2 (<i>all data</i>)	0.1116		
Crystal size Goodness-of-fit on F2	0.265 × 0.159 × 0.051 mm		
Reflections collected/unique	6327/1361[R(int) = 0.0435]		

Table S4. Crystal Data of **Linear-Et** Form 1: CCDC-2305892

Empirical Fomura	C ₂₀ H ₁₆ N ₂ O ₂		
Formula weight	316.36		
Crystal System	monoclinic		
Space Group	<i>P</i> 2 ₁ /c (#14)		
Unit cell dimensions	<i>a</i> = 10.5642	α = 90	
	<i>b</i> = 4.6703	β = 105.796	
	<i>c</i> = 16.2364	γ = 90	
<i>V</i>	770.82 Å ³		
<i>Z</i>	4		
Density (calculated)	1.363 g/cm ³		
R1 [I>2σ(I)]	0.053		
wR2 (<i>all data</i>)	0.1406		
Crystal size Goodness-of-fit on F2	0.756 × 0.182 × 0.119 mm		
Reflections collected/unique	4662/1546[R(int) = 0.0354]		

Table S5. Crystal Data of **Linear-Et** Form 2: CCDC-2305893

Empirical Fomura	C ₂₀ H ₁₆ N ₂ O ₂	
Formula weight	316.36	
Crystal System	triclinic	
Space Group	<i>P</i> -1 (#2)	
Unit cell dimensions	<i>a</i> = 4.6059	α = 89.474
	<i>b</i> = 8.2192	β = 85.283
	<i>c</i> = 10.0903	γ = 84.126
<i>V</i>	378.69 Å ³	
<i>Z</i>	2	
Density (calculated)	1.387 g/cm ³	
R1 [I>2σ(I)]	0.0629	
wR2 (<i>all data</i>)	0.1805	
Crystal size Goodness-of-fit on F2	0.304 × 0.083 × 0.038mm	
Reflections collected/unique	3407/1468[R(int) = 0.0422]	

Table S6. Crystal Data of **Linear-*n* Pr**: CCDC-2305894

Empirical Fomura	C ₂₂ H ₂₀ N ₂ O ₂	
Formula weight	344.41	
Crystal System	monoclinic	
Space Group	<i>P</i> 2 ₁ /c (#14)	
Unit cell dimensions	<i>a</i> = 4.7476	α = 90
	<i>b</i> = 8.2212	β = 92.392
	<i>c</i> = 22.6292	γ = 90
<i>V</i>	882.47 Å ³	
<i>Z</i>	4	
Density (calculated)	1.296 g/cm ³	
R1 [I>2σ(I)]	0.0428	
wR2 (<i>all data</i>)	0.1214	
Crystal size Goodness-of-fit on F2	0.462 × 0.185 × 0.06mm	
Reflections collected/unique	6364/1752[R(int) = 0.0326]	

Table S7. Crystal Data of **Linear-*i*Pr:** CCDC-2305895

Empirical Fomura	C ₂₂ H ₂₀ N ₂ O ₂		
Formula weight	344.41		
Crystal System	monoclinic		
Space Group	<i>P</i> 2 ₁ /c (#14)		
Unit cell dimensions	<i>a</i> = 11.3694	α = 90	
	<i>b</i> = 4.9871	β = 98.944	
	<i>c</i> = 15.6263	γ = 90	
<i>V</i>	875.24 Å ³		
<i>Z</i>	4		
Density (calculated)	1.307 g/cm ³		
R1 [I>2σ(I)]	0.0425		
wR2 (<i>all data</i>)	0.1129		
Crystal size Goodness-of-fit on F2	0.716 × 0.158 × 0.102mm		
Reflections collected/unique	11654/1765[R(int) = 0.0392]		

Table S8. Crystal Data of **Linear-*n*Bu:** CCDC-2305896

Empirical Fomura	C ₂₄ H ₂₄ N ₂ O ₂		
Formula weight	372.47		
Crystal System	triclinic		
Space Group	<i>P</i> -1 (#2)		
Unit cell dimensions	<i>a</i> = 4.6829	α = 89.289	
	<i>b</i> = 8.209	β = 86.831	
	<i>c</i> = 12.7307	γ = 85.18	
<i>V</i>	486.90 Å ³		
<i>Z</i>	2		
Density (calculated)	1.270 g/cm ³		
R1 [I>2σ(I)]	0.0647		
wR2 (<i>all data</i>)	0.2177		
Crystal size Goodness-of-fit on F2	0.354 × 0.134 × 0.055mm		
Reflections collected/unique	5841/1953[R(int) = 0.0499]		

Table S9. Crystal Data of **Linear-s Bu**: CCDC-2305897

Empirical Fomura	C ₂₄ H ₂₄ N ₂ O ₂		
Formula weight	372.47		
Crystal System	triclinic		
Space Group	<i>P</i> -1 (#2)		
Unit cell dimensions	<i>a</i> = 5.0896	α = 88.944	
	<i>b</i> = 6.4884	β = 86.138	
	<i>c</i> = 15.6421	γ = 76.245	
<i>V</i>	500.60 Å ³		
<i>Z</i>	2		
Density (calculated)	1.235 g/cm ³		
R1 [I>2σ(I)]	0.0806		
wR2 (<i>all data</i>)	0.2482		
Crystal size Goodness-of-fit on F2	0.285 × 0.033 × 0.017mm		
Reflections collected/unique	4594/1934[R(int) = 0.0459]		

Table S10. Crystal Data of **Linear-*n* Amyl**: CCDC-2305898

Empirical Fomura	C ₂₆ H ₂₈ N ₂ O ₂		
Formula weight	400.52		
Crystal System	triclinic		
Space Group	<i>P</i> -1 (#2)		
Unit cell dimensions	<i>a</i> = 4.7285	α = 95.036	
	<i>b</i> = 8.2545	β = 91.036	
	<i>c</i> = 13.9117	γ = 96.682	
<i>V</i>	537.00 Å ³		
<i>Z</i>	2		
Density (calculated)	1.238 g/cm ³		
R1 [I>2σ(I)]	0.069		
wR2 (<i>all data</i>)	0.2051		
Crystal size Goodness-of-fit on F2	0.239 × 0.091 × 0.026mm		
Reflections collected/unique	5319/2100[R(int) = 0.0396]		

Table S11. Crystal Data of **Linear-*t* Amyl:** CCDC-2305899

Empirical Fomura	C ₂₆ H ₃₀ N ₂ O ₂	
Formula weight	400.52	
Crystal System	monoclinic	
Space Group	<i>P</i> 2 ₁ /c (#14)	
Unit cell dimensions	<i>a</i> = 6.5784	α = 90
	<i>b</i> = 11.0323	β = 99.443
	<i>c</i> = 15.2453	γ = 90
<i>V</i>	1091.43 Å ³	
<i>Z</i>	4	
Density (calculated)	1.219 g/cm ³	
R1 [I>2σ(I)]	0.046	
wR2 (<i>all data</i>)	0.1283	
Crystal size Goodness-of-fit on F2	0.715 × 0.179 × 0.076mm	
Reflections collected/unique	8424/2196[R(int) = 0.0329]	

Table S12. Crystal Data of **Linear-*n* Hex:** CCDC-2305900

Empirical Fomura	C ₂₈ H ₃₂ N ₂ O ₂	
Formula weight	428.58	
Crystal System	triclinic	
Space Group	<i>P</i> -1 (#2)	
Unit cell dimensions	<i>a</i> = 4.6872	α = 88.441
	<i>b</i> = 8.137	β = 87.919
	<i>c</i> = 15.3378	γ = 85.811
<i>V</i>	582.86 Å ³	
<i>Z</i>	2	
Density (calculated)	1.221 g/cm ³	
R1 [I>2σ(I)]	0.0703	
wR2 (<i>all data</i>)	0.2382	
Crystal size Goodness-of-fit on F2	0.629 × 0.114 × 0.06mm	
Reflections collected/unique	6945/2310[R(int) = 0.0843]	

Table S13. Crystal Data of **Linear-*c* Hex** Form 1: CCDC-2305901

Empirical Fomura	C ₂₈ H ₂₈ N ₂ O ₂	
Formula weight	428.58	
Crystal System	monoclinic	
Space Group	<i>P</i> 2 ₁ /c (#14)	
Unit cell dimensions	<i>a</i> = 11.9199	α = 90
	<i>b</i> = 4.7806	β = 92.523
	<i>c</i> = 18.7426	γ = 90
<i>V</i>	1067.00 Å ³	
<i>Z</i>	4	
Density (calculated)	1.321 g/cm ³	
R1 [I>2σ(I)]	0.0461	
wR2 (all data)	0.1297	
Crystal size Goodness-of-fit on F2	0.679 × 0.254 × 0.127mm	
Reflections collected/unique	6689/2120[R(int) = 0.0316]	

Table S14. Crystal Data of **Linear-*c* Hex** Form 2: CCDC-2305902

Empirical Fomura	C ₂₈ H ₂₈ N ₂ O ₂	
Formula weight	428.58	
Crystal System	triclinic	
Space Group	<i>P</i> -1 (#2)	
Unit cell dimensions	<i>a</i> = 5.2466	α = 90.874
	<i>b</i> = 5.2604	β = 92.964
	<i>c</i> = 20.0763	γ = 102.471
<i>V</i>	540.09 Å ³	
<i>Z</i>	2	
Density (calculated)	1.305 g/cm ³	
R1 [I>2σ(I)]	0.0496	
wR2 (all data)	0.1594	
Crystal size Goodness-of-fit on F2	1.16 × 0.301 × 0.272mm	
Reflections collected/unique	8213/2557[R(int) = 0.0368]	

0

Reference

- S1) S. Nakamura, K. Okubo, Y. Nishii, K. Hirano, N. Tohnai, M. Miura, *Chem. Eur. J.* **2023**, e202302605.
- S2) S. Nakamura, M. Tsuboi, T. Taniguchi, Y. Nishii, N. Tohnai, M. Miura, *Chem. Lett.* **2020**, 49, 921-924.
- S3) T. Lu, F. Chen, *J. Comput. Chem.* **2012**, 33, 580-592.

- S4) A. Gavezzotti, *Acc. Chem. Res.* **1994**, *27*, 309-314.
S5) A. Gavezzotti, G. Filippini, *J. Phys. Chem.* **1994**, *98*, 4831-4837.